Bill Text: CA AB319 | 2019-2020 | Regular Session | Amended
Bill Title: Narcotic treatment: medication-assisted treatment: Drug Medi-Cal.
Sponsorship: Slight Partisan Bill (Republican 2-1)
Status: (Failed) 2020-02-03 - From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. [AB319 Detail]
Download: California-2019-AB319-Amended.html
|
Amended
IN
Assembly
March 25, 2019 |
| Assembly Bill | No. 319 |
| Introduced by Assembly Members Blanca Rubio and Waldron (Coauthor: Senator Stone) |
January 30, 2019 |
LEGISLATIVE COUNSEL'S DIGEST
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NOBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 14021.515 is added to the Welfare and Institutions Code, immediately following Section 14021.51, to read:14021.515.
(a) The department shall establish reimbursement rates and rate billing codes for medications authorized for use pursuant to subdivision (d) of Section 11839.2 of the Health and Safety Code that include the services specified in subdivision (f) of Section 14021.51 that are provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the United States Food and Drug Administration for patients with a substance use disorder.The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:
(a)Methadone.
(b)Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.
(c)Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.
(d)Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment
of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.
(e)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
